

INPLASY PROTOCOL

To cite: Chiu et al. Impact of area under the curve-based vancomycin dosing combination with anti-pseudomonal beta-lactam antibiotics: a systematic review and meta-analysis. Inplasy protocol 2022120025. doi: 10.37766/inplasy2022.12.0025

Received: 06 December 2022

Published: 06 December 2022

Corresponding author:
Chia-Yu Chiu

chia-yu.chiu@uth.tmc.edu

Author Affiliation:
The University of Texas Health
Science Center at Houston.

Support: No.

Review Stage at time of this submission: Completed but not published.

Conflicts of interest:
None declared.

Impact of area under the curve-based vancomycin dosing combination with anti-pseudomonal beta-lactam antibiotics: a systematic review and meta-analysis

Chiu, CY¹; Amara, S².

Review question / Objective: Did AUC-based vancomycin dosing reduce acute kidney injury than trough-based dosing when combined with anti-pseudomonal beta-lactam antibiotic?

Condition being studied: Patients received Vancomycin combined with anti-pseudomonal beta-lactam antibiotics and monitor with either trough-base dosing or AUC-based dosing vancomycin.

Information sources: All study types except case reports, case series, and conference abstracts were considered. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to November 2022.

INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 06 December 2022 and was last updated on 06 December 2022 (registration number INPLASY2022120025).

INTRODUCTION

Review question / Objective: Did AUC-based vancomycin dosing reduce acute kidney injury than trough-based dosing when combined with anti-pseudomonal beta-lactam antibiotic?

Rationale: Vancomycin combined with piperacillin/tazobactam (VPT) has a higher risk of acute kidney injury (AKI) than vancomycin combined with cefepime or meropenem. However, it is uncertain if area under the curve (AUC)-based vancomycin dosing is superior to trough-based dosing in these combinations.

Condition being studied: Patients received Vancomycin combined with anti-pseudomonal beta-lactam antibiotics and monitor with either trough-base dosing or AUC-based dosing vancomycin.

METHODS

Search strategy: ((Vancomycin area under the concentration-time curve) OR (Vancomycin AUC)) AND ((piperacillin-tazobactam) OR (ceftazidime) OR (cefoperazone-sulbactam) OR (cefepime) OR (imipenem-cilastatin) OR (doripenem) OR (meropenem) OR (beta-lactam)).

Participant or population: Patients received Vancomycin combined with anti-pseudomonal beta-lactam antibiotics and monitor with either trough-base dosing or AUC-based dosing vancomycin. Patients received Vancomycin combined with piperacillin/tazobactam (VPT) and monitor with either trough base dosing or AUC based dosing vancomycin.

Intervention: AUC based vancomycin dosing.

Comparator: Trough based vancomycin dosing.

Study designs to be included: Retrospective, prospective, randomized controlled trial.

Eligibility criteria: vancomycin combined with anti-pseudomonal beta-lactam antibiotics.

Information sources: All study types except case reports, case series, and conference abstracts were considered. PubMed, Embase, Cochrane Library, and ClinicalTrials.gov were searched from inception to November 2022.

Main outcome(s): The primary outcome is the odds ratio (OR) of AKI in patients who received VPT or the control using the AUC-based vancomycin dosing.

Additional outcome(s): The secondary outcomes are (1) the OR of AKI in patients

received VPT using AUC-based vancomycin dosing or trough-based dosing and (2) daily vancomycin dose in patients who received VPT using AUC-based dosing or trough-based dosing.

Data management: A random effects model was employed. Between-trial heterogeneity was determined by using I² tests; an I² > 50% was considered statistically significant heterogeneity. Funnel plots and Egger's test were used to examine potential publication bias. Statistical significance was defined as p values < 0.05, except for the determination of publication bias that employed p < 0.10. All analyses were performed using comprehensive meta-analysis (CMA) software, version 3 (Biostat, Englewood, NJ, USA).

Quality assessment / Risk of bias analysis: The methodological quality of enrolled studies was evaluated using Newcastle-Ottawa Quality Assessment Scale. Newcastle-Ottawa Quality Assessment Scale contains nine items in three categories: participant selection, comparability, and exposure.

Strategy of data synthesis: All eligible articles were reviewed. First author, year, sample size, number and type of treatment arms, and participant characteristics were recorded.

Subgroup analysis: The secondary outcomes are (1) the OR of AKI in patients received VPT using AUC-based vancomycin dosing or trough-based dosing and (2) daily vancomycin dose in patients who received VPT using AUC-based dosing or trough-based dosing.

Sensitivity analysis: Between-trial heterogeneity was determined by using I² tests; an I² > 50% was considered statistically significant heterogeneity. Funnel plots and Egger's test were used to examine potential publication bias.

Language restriction: Only English literature.

Country(ies) involved: USA (The University of Texas Health Science Center at Houston).

Keywords: vancomycin, piperacillin-tazobactam, area under the curve, vancomycin trough, acute kidney injury.

Dissemination plans: officially publish.

Contributions of each author:

Author 1 - Chia-Yu Chiu - Chia-Yu Chiu and Amara Sarwal were responsible for conceptualization, data curation, and manuscript writing. Chia-Yu Chiu was also responsible for software. All authors critically revised and approved the final version of the manuscript.

Email: chia-yu.chiu@uth.tmc.edu

Author 2 - Amara Sarwal - Chia-Yu Chiu and Amara Sarwal were responsible for conceptualization, data curation, and manuscript writing. Chia-Yu Chiu was also responsible for software. All authors critically revised and approved the final version of the manuscript.